David Jayne

Dr. David Jayne

Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, LS9 7TF, UK

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2017 in JAMA
Verified
Journal Article
Open access
PDF file
DJDavid Jayne
David Jayne
APAlessio Pigazzi
Alessio Pigazzi
HMHelen Marshall
Helen Marshall
JCJulie Croft
Julie Croft
NCNeil Corrigan
Neil Corrigan
JBJulia Brown
Julia Brown
Laparoscopic surgery is increasingly used for the treatment of colon cancer, but its use for rectal cancer is more controversial. Two recent, large, multicenter randomized clinical trials1,2 support laparoscopic surgery, and 2 other major trials3,4 report evidence that does not allow a designation of noninferior as compared with open surgery.

6 November 2012 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
BGB. L. Green
B. L. Green
HMH. C. Marshall
H. C. Marshall
FCF. Collinson
F. Collinson
PQP. Quirke
P. Quirke
PGP. Guillou
P. Guillou
JBJ. M. Brown
J. M. Brown
Background: Laparoscopic resection is used widely in the management of colorectal cancer; however, the data on long‐term outcomes, particularly those related to rectal cancer, are limited. The results of long‐term follow‐up of the UK Medical Research Council trial of laparoscopically assisted versus open surgery for colorectal cancer are presented. Methods: A total of 794 patients from 27 UK centres were randomized to laparoscopic or open surgery in a 2:1 ratio between 1996 and 2002. Long‐term follow‐up data were analysed to determine differences in survival outcomes and recurrences for intention‐to‐treat and actual treatment groups. Results: Median follow‐up of all patients was 62·9 (interquartile range 22·9 − 92·8) months. There were no statistically significant differences between open and laparoscopic groups in overall survival (78·3 (95 per cent confidence interval (c.i.) 65·8 to 106·6) versus 82·7 (69·1 to 94·8) months respectively; P = 0·780) and disease‐free survival (DFS) (89·5 (67·1 to 121·7) versus 77·0 (63·3 to 94·0) months; P = 0·589). In colonic cancer intraoperative conversions to open surgery were associated with worse overall survival (hazard ratio (HR) 2·28, 95 per cent c.i. 1·47 to 3·53; P < 0·001) and DFS (HR 2·20, 1·31 to 3·67; P = 0·007). In terms of recurrence, no significant differences were observed by randomized procedure. However, at 10 years, right colonic cancers showed an increased propensity for local recurrence compared with left colonic cancers: 14·7 versus 5·2 per cent (difference 9·5 (95 per cent c.i. 2·3 to 16·6) per cent; P = 0·019). Conclusion: Long‐term results continue to support the use of laparoscopic surgery for both colonic and rectal cancer. Copyright © 2012 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

13 September 2011 in International Journal of Colorectal Disease
Verified
Journal Article
Open access
PDF file
FCFiona J. Collinson
Fiona J. Collinson
DJDavid Jayne
David Jayne
APAlessio Pigazzi
Alessio Pigazzi
CTCharles Tsang
Charles Tsang
JBJennifer M. Barrie
Jennifer M. Barrie
JBJulia M. B. Brown
Julia M. B. Brown
There is growing enthusiasm for robotic-assisted laparoscopic operations across many surgical specialities, including colorectal surgery, often not supported by robust clinical or cost-effectiveness data. A proper assessment of this new technology is required, prior to widespread recommendation or implementation. The ROLARR trial is a pan-world, prospective, randomised, controlled, unblinded, superiority trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer. It will investigate differences in terms of the rate of conversion to open operation, rate of pathological involvement of circumferential resection margin, 3-year local recurrence, disease-free and overall survival rates and also operative morbidity and mortality, quality of life and cost-effectiveness. The primary outcome measure is the rate of conversion to open operation. For 80% power at the 5% (two-sided) significance level, to identify a relative 50% reduction in open conversion rate (25% to 12.5%), 336 patients will be required. The target recruitment is 400 patients overall to allow loss to follow-up. Patients will be followed up at 30 days and 6 months post-operatively and then annually until 3 years after the last patient has been randomised. In many centres, robotic-assisted surgery is being implemented on the basis of theoretical advantages, which have yet to be confirmed in practice. Robotic surgery is an expensive health care provision and merits robust evaluation. The ROLARR trial is a pragmatic trial aiming to provide a comprehensive evaluation of both robotic-assisted and standard laparoscopic surgery for the curative resection of rectal cancer.

11 December 2018 in Journal of Medical Internet Research
Verified
Journal Article
Open access
CDCandice Downey
Candice Downey
RRRebecca Randell
Rebecca Randell
JBJulia Brown
Julia Brown
DJDavid Jayne
David Jayne
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Vital signs monitoring is a universal tool for the detection of postoperative complications, but unwell patients can be missed in between traditional observation rounds. New remote monitoring technologies promise to convey the benefits of continuous monitoring to patients on general wards. Objective: The aim of this pilot study was to evaluate whether continuous remote vital signs monitoring is a practical and acceptable way of monitoring surgical patients, and to optimise the delivery of a definitive trial. Methods: A prospective, cluster-randomised, parallel-group, unblinded controlled pilot study was performed. Patients admitted to two surgical wards at a large tertiary hospital received either continuous and intermittent vital signs monitoring, or intermittent monitoring alone using an early warning score system. Continuous monitoring was provided by a wireless patch, worn on the patient’s chest, with data transmitted wirelessly every two minutes to a central monitoring station or a mobile device carried by the patient’s nurse. The primary outcome measure was time to administration of antibiotics in sepsis. Secondary outcome measures included length of hospital stay, 30-day readmission rate, mortality and patient acceptability. Results: 226 patients were randomised between January and June 2017. 140 patients were randomised to continuous remote monitoring; 86 patients were randomised to receive intermittent monitoring alone. On average, patients receiving continuous monitoring were administered antibiotics faster after evidence of sepsis (626 minutes, n=22, 95% CI 431.7-820.3 minutes, versus 1012.8 minutes, n=12, 95% CI 425.0-1600.6 minutes), had a shorter average length of hospital stay (13.3 days, 95% CI 11.3-15.3 days, versus 14.6 days, 95% CI 11.5-17.7 days) and were less likely to require readmission within 30 days of discharge (11.4%, 95% CI 6.16%-16.7%, versus 20.9%, 95% CI 12.3%-29.5%). Wide confidence intervals suggest these differences are not statistically significant. Patients found the monitoring device to be acceptable in terms of comfort and perceived an enhanced sense of safety, despite 34% discontinuing the intervention early. Conclusions: Remote continuous vital signs monitoring on surgical wards is practical and acceptable to patients. Large, well-controlled studies in high-risk populations are required to determine if the observed trends translate into a significant benefit for continuous over intermittent monitoring. Clinical Trial: The study was prospectively registered on the ISRCTN registry on 19th December 2016 under registry number ISRCTN60999823; URL: https://doi.org/10.1186/ISRCTN60999823.

12 November 2013 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
JBJenifer Barrie
Jenifer Barrie
DJDavid Jayne
David Jayne
JWJudy Wright
Judy Wright
CMCarolyn J. Czoski Murray
Carolyn J. Czoski Murray
FCFiona J. Collinson
Fiona J. Collinson
SPSue H. Pavitt
Sue H. Pavitt

27 June 2018 in Trials
Verified
Journal Article
Open access
PDF file
NCNeil Corrigan
Neil Corrigan
HMHelen Marshall
Helen Marshall
JCJulie Croft
Julie Croft
JCJoanne Copeland
Joanne Copeland
DJDavid Jayne
David Jayne
JBJulia Brown
Julia Brown
Commonly in surgical randomised controlled trials (RCT) the experimental treatment is a relatively new technique which the surgeons may still be learning, while the control is a well-established standard. This can lead to biased comparisons between treatments. In this paper we discuss the implementation of approaches for addressing this issue in the ROLARR trial, and points of consideration for future surgical trials. ROLARR was an international, randomised, parallel-group trial comparing robotic vs. laparoscopic surgery for the curative treatment of rectal cancer. The primary endpoint was conversion to open surgery (binary). A surgeon inclusion criterion mandating a minimum level of experience in each technique was incorporated. Additionally, surgeon self-reported data were collected periodically throughout the trial to capture the level of experience of every participating surgeon. Multi-level logistic regression adjusting for operating surgeon as a random effect is used to estimate the odds ratio for conversion to open surgery between the treatment groups. We present and contrast the results from the primary analysis, which did not account for learning effects, and a sensitivity analysis which did. The primary analysis yields an estimated odds ratio (robotic/laparoscopic) of 0.614 (95% CI 0.311, 1.211; p = 0.16), providing insufficient evidence to conclude superiority of robotic surgery compared to laparoscopic in terms of the risk of conversion to open. The sensitivity analysis reveals that while participating surgeons in ROLARR were expert at laparoscopic surgery, some, if not all, were still learning robotic surgery. The treatment-effect odds ratio decreases by a factor of 0.341 (95% CI 0.121, 0.960; p = 0.042) per unit increase in log-number of previous robotic operations performed by the operating surgeon. The odds ratio for a patient whose operating surgeon has the mean experience level in ROLARR – 152.46 previous laparoscopic, 67.93 previous robotic operations – is 0.40 (95% CI 0.168, 0.953; p = 0.039). In this paper we have demonstrated the implementation of approaches for accounting for learning in a practical example of a surgery RCT analysis. The results demonstrate the value of implementing such approaches, since we have shown that without them the ROLARR analysis would indeed have been confounded by the learning effects. International Standard Randomised Controlled Trial Number (ISRCTN) registry, ID: ISRCTN80500123. Registered on 27 May 2010.